CN110621328A - 含有阳春砂提取物的预防、改善或治疗肥胖的组合物 - Google Patents
含有阳春砂提取物的预防、改善或治疗肥胖的组合物 Download PDFInfo
- Publication number
- CN110621328A CN110621328A CN201880026614.3A CN201880026614A CN110621328A CN 110621328 A CN110621328 A CN 110621328A CN 201880026614 A CN201880026614 A CN 201880026614A CN 110621328 A CN110621328 A CN 110621328A
- Authority
- CN
- China
- Prior art keywords
- amomum villosum
- extract
- obesity
- preventing
- fat diet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 244000141331 Amomum villosum Species 0.000 title claims abstract description 66
- 208000008589 Obesity Diseases 0.000 title claims abstract description 55
- 235000020824 obesity Nutrition 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 235000009200 high fat diet Nutrition 0.000 claims description 44
- 108010016731 PPAR gamma Proteins 0.000 claims description 10
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 claims description 10
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims description 8
- 241000699670 Mus sp. Species 0.000 claims description 8
- 102000011690 Adiponectin Human genes 0.000 claims description 7
- 108010076365 Adiponectin Proteins 0.000 claims description 7
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims description 7
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 claims description 7
- 102000000536 PPAR gamma Human genes 0.000 claims description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 5
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 108091008324 binding proteins Proteins 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 238000013116 obese mouse model Methods 0.000 claims description 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 claims 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 230000004136 fatty acid synthesis Effects 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 abstract description 19
- 230000002401 inhibitory effect Effects 0.000 abstract description 17
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000003579 anti-obesity Effects 0.000 abstract description 5
- 241000700159 Rattus Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 208000004930 Fatty Liver Diseases 0.000 description 9
- 206010019708 Hepatic steatosis Diseases 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 208000010706 fatty liver disease Diseases 0.000 description 9
- 231100000240 steatosis hepatitis Toxicity 0.000 description 9
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000004576 sand Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 230000011759 adipose tissue development Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 241001127714 Amomum Species 0.000 description 1
- 241001571352 Amomum longiligulare Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 244000307545 Elaeagnus angustifolia Species 0.000 description 1
- 235000017643 Elaeagnus angustifolia Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241001071917 Lithospermum Species 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及含有有效成分阳春砂提取物的预防及改善肥胖的组合物。本发明涉及含有阳春砂提取物的预防及改善肥胖的组合物，其特征为所述阳春砂提取物是用水提取的，以老鼠经口给药基准含100～500mg/kg阳春砂提取物是。本发明的含有阳春砂提取物的预防、改善或治疗肥胖的组合物，所述阳春砂提取物通过抑制肝内脂肪细胞增加、抑制脂肪细胞的大小、抑制甘油三酯的生成的效能及机制，在生物体内抑制mRNA表达，因此具有抗肥胖效果。
Description
技术领域
本发明涉及含有阳春砂提取物的预防、治疗或改善肥胖的组合物。
本发明提供一种含有阳春砂提取物的预防、治疗或改善肥胖的组合物，所述阳春砂提取物通过抑制肝内脂肪生成、抑制脂肪细胞大小、抑制甘油三酯生成，抑制脂肪细胞分化相关基因mRNA的表达及抑制脂肪肝诱发mRNA表达，具有预防及改善肥胖的效果。
背景技术
现代人由于营养过剩以及摄入和能量消耗之间的不均衡引发的代谢障碍，在体内过度蓄积脂肪，肥胖人群增加。
这种肥胖人口逐渐增加，2008年全世界成人人口中15亿人为超重及肥胖，推算2030年超重人口将超过大约21亿人。
尤其，儿童期形成的肥胖症表现为脂肪细胞的大小和细胞数增加的形态，若减少体重，脂肪细胞的大小减小，但是细胞数一生都不减少，所以危险。
不同于此，成人的脂肪细胞显示虽然肥大但不增加的形态。肥胖的分布具有以腹部为中心局限于体干的趋势。
即，虽然成人的脂肪细胞仅大小增加，但是少儿期开始的肥胖则脂肪细胞的大小和脂肪细胞的数量同时增加，即使在成人后减少体重，由于只是暂时减小脂肪细胞的大小，脂肪细胞的数量仍然是多的状态，因此容易复胖。
另外，最近随着营养状态变好和成人的增加，脂肪肝患者增加。这是一种过度摄入脂肪引起的肝内脂肪蓄积及合成且无法正常进行脂肪代谢而发病的疾病。
脂肪肝患者的70～80％为肥胖，其余相当数患者为超重。因此，减少体重，提高胰导素敏感性以使脂肪肝好转，最近，据报道仅减少体重的5％左右也可以改善胰导素抵抗且肝功能数值好转。因此，生活习惯的改善比什么都重要。
因此，最近面对肥胖的严重性，面世了作为减肥辅助剂的多样的产品，但是实际上导致胃炎、便秘、食欲不振等副作用。
本申请人利用阳春砂(Amomum villosum Loureiro)提取物提出本发明，其没有副作用，长期服用也没有毒性，对改善肥胖有效果。
砂仁指生姜科(Zingiberaceae)所属的绿壳砂(Amomum villosum Loureirovar.xanthioides T.L.Wu et Senjen)或阳春砂(Amomum villosum Loureiro)的成熟的果实或种子的块，本发明中使用阳春砂的果实作为材料。
阳春砂主要产于福建、广东、广西、云南，绿壳砂主要产于柬埔寨、印度、老挝、缅甸、泰国、越南等中南半岛区域和中国的广西、云南的部分地区。(摘自中国植物志(Floraof China，v24:347-356.2000))。由于产地不同，古代将绿壳砂别称为“缩砂仁”。
另外，目前的情况是中国认证为正品但在韩国视为假货的海南砂(Amomumlongiligulare T.L.Wu)的果实也大量流通。但是，申等(SHEN Li WANG Yang JIANG Ku etal.Comparison of HPLC Fingerprints of Amomum villosum Lour.，Amomurn villosumLour.var.xanthioides T.L.Wu et Senjen and Amomum longiligulare T.L.Wu.中国药学杂志.2016:51(12)；1039-1043.)经RP-HPLC研究结果，表示3种砂仁在成分上显示高的类似度，但是海南砂和阳春砂的化学成分类似，相反绿壳砂与前两种有明显的差异，需要对其进行详细的药理和临床效能的比较。
对此，本发明为了证明阳春砂提取物的预防及改善肥胖的效能，利用高脂肪饮食诱导肥胖模型，通过在生物体内抑制肝内脂肪生成、抑制脂肪细胞大小、抑制甘油三酯生成、抑制脂肪细胞分化相关mRNA、脂肪肝诱发mRNA表达，证明了阳春砂提取物的预防、改善及治疗肥胖的效能，由此完成了本发明。
另外，根据现有文献，大韩民国注册专利公报第10-1431610号记载有作为有效成分含乌梅及紫草提取物的用于预防或治疗肥胖、异常血脂症、脂肪肝或糖尿的药剂学组合物，大韩民国注册专利公报第10-1206543号记载有含栗壳提取物的组成物对预防或治疗脂肪肝有效果。
但是，上述现有技术文献使用不同于阳春砂的其它天然物揭示效能，在这一点上区别于本发明。
发明内容
技术课题
本发明的技术课题是提供一种含有阳春砂提取物的抗肥胖组合物，利用高脂肪饮食诱导的肥胖模型，确认了阳春砂提取物的抗肥胖效能。
本发明的技术课题是提供一种含有阳春砂提取物的预防、改善或治疗肥胖的组合物，为了证明阳春砂提取物的预防及改善肥胖的效果，利用高脂肪饮食诱导的肥胖模型，在生物体内，通过抑制肝内脂肪生成、抑制脂肪细胞大小、抑制甘油三酯生成、抑制脂肪细胞分化相关mRNA、脂肪肝诱发mRNA表达，确认了阳春砂提取物的预防及改善肥胖的效能。
课题解决方案
本发明提供预防、改善或治疗肥胖的组合物，含有阳春砂提取物，从而解决技术课题。
本发明提供预防及改善肥胖的组合物，其特征在于，以老鼠经口给药基准含100～500mg/kg所述阳春砂提取物，从而解决技术课题。
本发明提供预防及改善肥胖的组合物，所述阳春砂提取物是用水提取的，从而解决技术课题。
本发明提供用于预防及改善肥胖的组合物，所述阳春砂提取物在高脂肪饮食诱导的肥胖老鼠中抑制甘油三酯的含量，在老鼠中抑制过氧化物酶体增殖物激活受体PPARγ(peroxisome proliferators-activated receptrorγ)、转录因子/增强子结合蛋白C/EBPα(CCAAT/enhancer binding proteinα)、脂肪酸合成酶FAS(fatty acid synthase)、固醇调节元件结合蛋白SREBP1(sterol regulatory element binding protein 1)、肿瘤坏死因子TNFα(tumor necrosis factorα)和脂联素mRNA(Adiponectin)的表达，从而解决技术课题。
本发明提供用于预防及改善肥胖的组合物，所述阳春砂提取物对由高脂肪饮食诱导的肥胖抑制甘油三酯生成，从而解决技术课题。
本发明提供用于改善肥胖的保健功能食品，含有阳春砂提取物作为有效成分，从而解决技术课题。
发明效果
根据本发明的实验例，为了确认阳春砂提取物对利用高脂肪饮食诱导肥胖模型的抗肥胖效能，在生物体内确认了脂肪蓄积抑制效能。
根据本发明的实验例，向高脂肪饮食诱导的肥胖模型老鼠给药所述阳春砂提取物的结果，抑制肝内脂肪生成，抑制脂肪细胞大小，抑制甘油三酯生成，抑制脂肪细胞分化相关mRNA、脂肪肝诱发mRNA表达，从而利用阳春砂提取物的预防、改善及治疗肥胖的效能，开发了含有阳春砂提取物的预防、改善及治疗肥胖的组成物，由此完成了本发明。
附图说明
图1是表示根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的动物体重变化的图。
图2是表示根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的肝和总脂肪量的变化的图。
图3是观察根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的肝内脂肪组织的图。
图4是观察根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的脂肪组织变化的图。
图5是分析根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的甘油三酯的含量的图表。
图6是确认根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的PPARγ和C/EBPα表达量的图。
图7是确认根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的FAS和SREBP1、mRNA表达量的图表。
图8是确认根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的TNFα和脂联素表达量的图表。
具体实施方式
本说明书及权利要求书中使用的用语或词语不应限定解释为通常或词典上的意义，根据发明人为了用最优选的方法说明自己的发明可以适当定义用语的概念的原则，应解释为符合本发明的技术思想的意义和概念。
因此，本说明书中记载的实施例、参照例及附图中所述的事项不过是本发明的最优选的一例，不代表本发明的全部技术思想，因此在本申请提出的时刻，应当理解可能存在代替它们的多样的等同物和变形例。
实验例1.利用高脂肪饮食诱导肥胖模型的阳春砂提取物的抗肥胖效果
1)阳春砂提取物的制造
阳春砂在圆光大学中医科大学本草学教室确认了真伪。本步骤是用水提取阳春砂而得到提取物的步骤。
根据设计条件，可以使用其它溶媒，根据提取溶媒的种类，可以不同地设计提取温度、提取时间、溶媒的量及残留成分处理方式等。提取溶媒也可以使用多种溶媒，可提取的溶媒有水、乙醇、甲醇、脂油、甘油、马油、乙酸乙酯、丙酮、丁醇及异丙醇等。
本发明中优选用水提取阳春砂。提取过程中，将100g阳春砂用3次蒸馏水900ml加热环流提取3小时，过滤之后，将滤液减压浓缩冻结干燥得到阳春砂水提取物9.25g之后，进行冷藏保管来用于实验。因此，可以开发出特征是用水提取的预防及改善肥胖的组合物。
3)实验动物的饲养及饮食
关于实验动物，购买六周龄的C57BL/6雄鼠(欧蓝生物(Orientbio)公司，韩国城南)，用一周使其适应饲养室环境。将平均体重大约20～22g的老鼠随机分配到正常饮食对照组(对照组)、高脂肪饮食对照组(High fat diet)、高脂肪饮食的100mg/kg阳春砂提取物给药组(High fat diet+AVE(100mg/kg))、高脂肪饮食的200mg/kg阳春砂提取物给药组(High fat diet+AVE(200mg/kg))、高脂肪饮食的500mg/kg阳春砂提取物给药组(High fatdiet+AVE(500mg/kg))，饲养了七周。
饲养室维持温度18～24°、相对湿度50～60％，明暗以12小时周期(8:00～20:00)调节。本实验使用的高脂肪饲料是在基本饮食中追加添加15％的猪油，使得总热量的大约60％以脂肪供给，一周测量一次体重。动物实验得到圆光大学动物伦理委员会(WonkwangUniversity Animal Experiment Ethics Committee)的承认，实验室动物的使用和管理遵循机构指引。
3)设定实验组及试剂给药
对结束驯化期间的实验动物测量了体重。实验组分为正常组(conrtrol group)、高脂肪饮食供给组(High fat diet)、高脂肪饲料+阳春砂提取物100mg/kg给药组、高脂肪饲料+阳春砂提取物200mg/kg给药组、高脂肪饲料+阳春砂提取物500mg/kg给药组，各组平均10只使用于实验，阳春砂提取物以规定的浓度每天利用老鼠用投药器给药七周。
图1是表示根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的动物体重变化的图。
其结果，可以确认体重随着阳春砂提取物的给药量增加而减小。即，可以制造以老鼠经口给药基准含有100～500mg/kg阳春砂提取物的预防、改善及治疗肥胖的组合物。
4)生物标志物分析及剖检
开始实验后每周测量体重，剖检是用乙醚麻醉后从腹部大静脉采血用于血液分析，摘出肝和脂肪(附睾脂肪)组织测重量。
图2是表示根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的肝和总脂肪量的变化的图。
其结果，可以确认肝和脂肪组织的重量随着阳春砂提取物的给药量增加而减小。
5)组织学分析
摘取的肝和脂肪组织，切取10％福尔马林(甲醛)液中固定的试料后，再用10％福尔马林液进行固定。然后，包埋于石蜡之后切片为5μm的厚度且切成薄片后用苏木精伊红(hematoxylin-eosin)染色。染色的肝和脂肪组织利用光学显微镜即Olympus BX50F4(奥林巴斯，日本)观察及拍摄。
图3是观察根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的肝内脂肪组织的图。
图4是观察根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的脂肪的组织变化的图。
其结果，随着阳春砂提取物的给药量增加，肝内脂肪减少，可以确认脂肪组织的大小减小。
6)总RNA分离
实验结束后，从摘出的肝和脂肪组织分离总RNA是利用Trizol试剂(生活科技(Life Technologies)公司，英国)，根据制造公司提供的方法进行。
将各组织切碎之后，用1000μl的RNAzol B溶解之后添加200μl氯仿，并在冰中使其反应5分钟。反应结束后在4℃以13,000rpm进行20分钟圆心分离得到的上层液移至新的试管。
在所述上层液添加同量的异丙醇混合之后，在冰中使其反应30分钟。反应结束之后，在4℃以13,000rpm进行20分钟圆心分离，用75％乙醇清洗两次沉淀物。干燥清洗后的RNA后，用20μl DEPC水溶解，在分光光度计中测量吸光度进行定量。
7)实时逆转录酶聚合反应(实时PCR)
逆转录反应(reverse transcription reaction)，利用2μg总RNA和PrimeScriptTM试剂盒(完美实时)(TaKaRa BIOINC.)，按照制造公司提供的方法执行。
逆转录反应是利用含有2μg总RNA、25pmol的oligo d(T)引物、PrimeScript RT酶混合物I、5倍primeScript缓冲液的反应液，在37℃反应15分钟，在85℃反应5小时合成cDNA。
实时逆转录酶聚合反应是利用Power SYBY GreenPCR Master Mix对稀释10倍的cDNA执行。表达的各基因的mRNA量利用LightCycler系统软件(System software(Roche))以相对于GAPDH的量计算。所使用的引物的序列示于表1。
[表1]用于实时PCR的正向及反向引物序列及登录号
图6是确认根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的PPARγ和C/EBPα表达量的图。
图7是确认根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的FAS和SREBP1、mRNA表达量的图表。
图8是确认根据阳春砂提取物的给药量的高脂肪饮食诱导肥胖模型的TNFα和脂联素表达量的图表。
其结果，由高脂肪饮食诱导肥胖老鼠中，可以确认根据阳春砂提取物的给药量抑制过氧化物酶体增殖物激活受体γ(PPARγ)、转录因子/增加子结合蛋白α(C/EBPα)、脂肪酸合成酶FAS、固醇调节元件结合蛋白1(SREBP1)、肿瘤坏死因子α(TNFα)和脂联素mRNA的表达，由此预测抑制脂肪细胞分化及表达，抑制脂肪肝表达。
从而能够制造预防、改善或治疗肥胖的给合物，其在由高脂肪饮食诱导的肥胖老鼠中抑制甘油三酯的含量，在老鼠中抑制过氧化物酶体增殖物激活受体γ(PPARγ)、转录因子/增加子结合蛋白α(C/EBPα)、脂肪酸合成酶(FAS)、固醇调节元件结合蛋白1(SREBP1)、肿瘤坏死因子α(TNFα)和脂联素mRNA的表达。
8)肝甘油三酯分析
肝甘油三酯含量如下测量。在体积比(v：v)2：1氯仿-甲醇溶液中均质化肝组织，在常温下反应1小时之后进行圆心分离，之后将有机溶媒层干燥24小时。在乙醇中溶解之后，肝的甘油三酯含量利用TG试剂盒(AM157S-K和AM 202-K，阿山法码(Asan Pharmaceutical)公司，韩国)检测，标准化为蛋白质浓度。
可以确认在高脂肪饮食诱导肥胖老鼠中，根据阳春砂提取物的给药量抑制甘油三酯的生成。
阳春砂提取物对高脂肪饮食导致的诱导肥胖抑制甘油三酯，由此开发出预防、改善或治疗肥胖的组合物。
8)统计分析
所有实验结果以平均±标准差(Mean±)计算。各组之间的基于统计方面有意性验证的统计分析是实施邓肯ANOVA(单因素方差分析)事后验证比较，当p<0.05时判定为有意(SPSS V12.，SPSS Inc，芝加哥，IL，美国)。
Claims (1)
1.一种用于预防或改善由高脂肪饮食导致的肥胖的保健功能食品组合物，作为有效成分含有阳春砂提取物，其特征在于，所述阳春砂提取物是用水提取的，以老鼠经口给药基准含100～500mg/kg的所述阳春砂提取物，所述阳春砂提取物在由高脂肪饮食诱导的肥胖老鼠中抑制甘油三酯的含量，在老鼠中抑制过氧化物酶体增殖物激活受体γ(PPARγ)、转录因子/增强子结合蛋白α(C/EBPα)、脂肪酸合成(FAS酶)、固醇调节元件结合蛋白1(SREBP1)、肿瘤坏死因子α(TNFα)和脂联素mRNA的表达。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170121948A KR101952644B1 (ko) | 2017-09-21 | 2017-09-21 | 양춘사 추출물을 함유하는 비만 예방, 개선 또는 치료 조성물 |
| KR10-2017-0121948 | 2017-09-21 | ||
| PCT/KR2018/010948 WO2019059606A1 (ko) | 2017-09-21 | 2018-09-18 | 양춘사 추출물을 함유하는 비만 예방, 개선 또는 치료 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110621328A true CN110621328A (zh) | 2019-12-27 |
Family
ID=65810821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880026614.3A Withdrawn CN110621328A (zh) | 2017-09-21 | 2018-09-18 | 含有阳春砂提取物的预防、改善或治疗肥胖的组合物 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3603657A4 (zh) |
| JP (1) | JP2020518282A (zh) |
| KR (1) | KR101952644B1 (zh) |
| CN (1) | CN110621328A (zh) |
| WO (1) | WO2019059606A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101952648B1 (ko) * | 2017-08-03 | 2019-02-27 | 국가식품클러스터지원센터 | 양춘사 추출물을 함유하는 지방간 예방 및 치료 개선 조성물 |
| KR102643099B1 (ko) * | 2020-01-31 | 2024-03-05 | 주식회사 일원바이오 | 양춘사 및 백출 복합 추출물을 유효성분으로 함유하는 고지혈증 또는 동맥경화의 예방, 개선 또는 치료용 조성물 |
| CN112608795B (zh) * | 2020-11-26 | 2023-11-07 | 福建中特药业有限公司 | 一种砂仁叶油以及水提-低温变压提取砂仁叶油的工艺方法 |
| KR20230114999A (ko) | 2022-01-26 | 2023-08-02 | 주식회사 일원바이오 | 양춘사 추출물을 유효성분으로 함유하는 대장염의 예방, 개선 또는 치료용 조성물 |
| KR20230172882A (ko) | 2022-06-16 | 2023-12-26 | 주식회사 한국인삼공사 | 방향성 오일 성분이 보존된 사인 추출물의 제조 방법 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101088403A (zh) * | 2006-06-14 | 2007-12-19 | 天津开发区帅嘉商贸行销有限责任公司 | 一种减肥除胀的保健食品及其制备方法 |
| CN105169203A (zh) * | 2015-09-25 | 2015-12-23 | 云南中医学院 | 一种砂仁提取物及其用途 |
| CN105902937A (zh) * | 2016-06-03 | 2016-08-31 | 李艳梅 | 治疗肥胖的中药组合物 |
| CN107029177A (zh) * | 2017-04-14 | 2017-08-11 | 董早霞 | 生蒲黄汤剂 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1133145A (zh) * | 1995-04-14 | 1996-10-16 | 禾力集团 | 身轻健饮品 |
| US20030228379A1 (en) * | 2002-05-28 | 2003-12-11 | Wenyuan Shi | Herbs and herbal combinations useful for the treatment of microbial infections |
| CN1202843C (zh) * | 2002-06-21 | 2005-05-25 | 天大药业(深圳)有限公司 | 一种戒毒药物组合物及其制备方法和应用 |
| KR101206543B1 (ko) | 2009-01-29 | 2012-11-30 | 한국생명공학연구원 | 율피 추출물을 포함하는 지방간의 예방 또는 치료용 조성물 |
| KR101637517B1 (ko) * | 2009-06-26 | 2016-07-11 | 에스케이바이오랜드 주식회사 | 비타민 ｕ를 유효성분으로 함유하는 비만 예방 또는 치료용 조성물 |
| KR101436213B1 (ko) * | 2012-10-19 | 2014-09-01 | 바이오스펙트럼 주식회사 | 긴잎모시풀 추출물을 포함하는 비만의 예방 또는 치료용 조성물 |
| CN103800794A (zh) * | 2012-11-13 | 2014-05-21 | 石树华 | 一种治疗肥胖性脂肪肝的中药配方 |
| US20150296851A1 (en) * | 2012-11-27 | 2015-10-22 | Shanghai Jiao Tong University | Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof |
| KR101431610B1 (ko) | 2013-01-30 | 2014-08-18 | 호서대학교 산학협력단 | 오매 및 자초 추출물을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 당뇨의 예방 또는 치료용 약제학적 조성물 |
| CN104367965A (zh) * | 2013-08-14 | 2015-02-25 | 王米乐 | 一种治疗肥胖症的组合物中药 |
| CN103446574B (zh) * | 2013-09-25 | 2015-07-15 | 张立东 | 一种治疗便秘和肥胖症的药物 |
| KR101559130B1 (ko) * | 2014-03-07 | 2015-10-08 | 동의대학교 산학협력단 | 한약재의 추출물을 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 |
| KR20160139953A (ko) * | 2015-05-29 | 2016-12-07 | 전주대학교 산학협력단 | 엉겅퀴 꽃 추출물을 유효성분으로 함유하는 항비만 조성물 |
| CN105360243A (zh) * | 2015-10-26 | 2016-03-02 | 安徽麦船食品科技有限公司 | 一种香辣牛肉饼干及其制备方法 |
| CN105853877B (zh) * | 2016-04-08 | 2020-01-07 | 北京中医药大学东方医院 | 一种减肥的药物组合物，含其制剂及其制备方法 |
| CN105920514A (zh) * | 2016-04-27 | 2016-09-07 | 青岛友诚高新技术有限公司 | 治疗代谢综合征的中药组合物 |
| CN106860853A (zh) * | 2017-04-10 | 2017-06-20 | 甘肃青黛百年健康管理股份有限公司 | 一类分型管理脂肪的食疗养生制剂 |
| KR101785495B1 (ko) * | 2017-06-21 | 2017-10-17 | 원광대학교산학협력단 | 감국 추출물 또는 분획물을 유효성분으로 포함하는 비만, 비만 관련 질환 또는 합병증의 예방, 개선 또는 치료용 조성물 |
-
2017
- 2017-09-21 KR KR1020170121948A patent/KR101952644B1/ko active
-
2018
- 2018-09-18 JP JP2020509413A patent/JP2020518282A/ja active Pending
- 2018-09-18 CN CN201880026614.3A patent/CN110621328A/zh not_active Withdrawn
- 2018-09-18 EP EP18857493.3A patent/EP3603657A4/en not_active Withdrawn
- 2018-09-18 WO PCT/KR2018/010948 patent/WO2019059606A1/ko unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101088403A (zh) * | 2006-06-14 | 2007-12-19 | 天津开发区帅嘉商贸行销有限责任公司 | 一种减肥除胀的保健食品及其制备方法 |
| CN105169203A (zh) * | 2015-09-25 | 2015-12-23 | 云南中医学院 | 一种砂仁提取物及其用途 |
| CN105902937A (zh) * | 2016-06-03 | 2016-08-31 | 李艳梅 | 治疗肥胖的中药组合物 |
| CN107029177A (zh) * | 2017-04-14 | 2017-08-11 | 董早霞 | 生蒲黄汤剂 |
Non-Patent Citations (3)
| Title |
|---|
| BING JIANG，等: "Potent Inhibitory Effect of Chinese Dietary Spices on Fatty Acid Synthase", 《PLANT FOODS HUMAN NUTRITION》 * |
| LONGQUAN YU，等: "Effects of Some Chinese Spices on Body Weights, Plasma Lipids, Lipid Peroxides, and Liver Lipids in Mice", 《FOOD SCIENCE AND TECHNOLOGY RESEARCH》 * |
| 方思佳，等: "单纯性肥胖中医药治疗进展", 《辽宁中医药大学学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101952644B1 (ko) | 2019-05-23 |
| EP3603657A1 (en) | 2020-02-05 |
| WO2019059606A1 (ko) | 2019-03-28 |
| JP2020518282A (ja) | 2020-06-25 |
| EP3603657A4 (en) | 2020-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110621328A (zh) | 含有阳春砂提取物的预防、改善或治疗肥胖的组合物 | |
| Wang et al. | Anti-obesity effect of Solidago virgaurea var. gigantea extract through regulation of adipogenesis and lipogenesis pathways in high-fat diet-induced obese mice (C57BL/6N) | |
| Sharma et al. | Anti-obesity effects of the mixture of Eriobotrya japonica and Nelumbo nucifera in adipocytes and high-fat diet-induced obese mice | |
| Choi et al. | Antiobesity effects of Salvia plebeia R. Br. extract in high-fat diet-induced obese mice | |
| Lee et al. | Antiadipogenic effects of Aster glehni extract: in vivo and in vitro effects | |
| Wang et al. | Effect of quercetin on lipids metabolism through modulating the gut microbial and AMPK/PPAR signaling pathway in broilers | |
| Sung et al. | Anti-obesity effects of Geranium thunbergii extract via improvement of lipid metabolism in high-fat diet-induced obese mice | |
| Bunkrongcheap et al. | Ivy gourd (Coccinia grandis L. Voigt) root suppresses adipocyte differentiation in 3T3-L1 cells | |
| Yimam et al. | Appetite suppression and antiobesity effect of a botanical composition composed of Morus alba, Yerba mate, and Magnolia officinalis | |
| Kim et al. | Red bean extract inhibits immobilization-induced muscle atrophy in C57BL/6N mice | |
| Son et al. | Antiobesity activity of Vigna nakashimae extract in high-fat diet-induced obesity | |
| Shao et al. | Expression analysis of microRNAs and their target genes during experimental diabetic renal lesions in rats administered with ginsenoside Rb1 and trigonelline | |
| Shin et al. | The Korean traditional medicine Gyeongshingangjeehwan inhibits adipocyte hypertrophy and visceral adipose tissue accumulation by activating PPARα actions in rat white adipose tissues | |
| Subramaniam et al. | The medicinal mushroom Ganoderma neo-japonicum (Agaricomycetes) polysaccharide extract prevents obesity-induced diabetes in C57BL/6J mice | |
| Ying-Ying et al. | Bofutsushosan ameliorates obesity in mice through modulating PGC-1α expression in brown adipose tissues and inhibiting inflammation in white adipose tissues | |
| Hassanpour et al. | The Effect of Interval and Continued Trainings with Crocin on Apoptotic Markers in the Heart Tissue of High-Fat Diet and Streptozotocin Induced Type 2 Diabetic Rats | |
| CN110327399B (zh) | 裸花紫珠提取物在制备降脂药物中的应用 | |
| KR101952648B1 (ko) | 양춘사 추출물을 함유하는 지방간 예방 및 치료 개선 조성물 | |
| US8168239B1 (en) | Method for the production of diet food with medicinal herbs | |
| Ye et al. | Water extract of Ferula lehmanni Boiss. prevents high-fat diet-induced overweight and liver injury by modulating the intestinal microbiota in mice | |
| JP4557231B2 (ja) | ケフィアを用いた薬剤およびその製造方法、健康食品 | |
| Kim et al. | Ethanol extracts of unroasted Coffea canephora robusta beans suppress adipogenesis in preadipocytes and fat accumulation in rats fed a high-fat diet | |
| KR101887764B1 (ko) | 항비만성 팥 껍질 추출물의 추출방법 및 이를 유효성분으로 함유하는 항비만 조성물 | |
| RU2419447C2 (ru) | Лекарственный сбор, обладающий гепатопротекторной и противовоспалительной активностями | |
| KR101325515B1 (ko) | 항비만 활성 및 지방간 예방 활성을 갖는 겨우살이 추출물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191227 |
|
| WW01 | Invention patent application withdrawn after publication |